1011484-22-2

Basic information

• Product Name: 4-FLUORO-3-METHYL-1H-INDOLE
• Synonyms: 4-FLUORO-3-METHYL-1H-INDOLE;4-fluoro-3-methyl-1H-indoleCAS Registry Number 1011484-22-2 ~6~14 C9 H8 F N 1H-Indole, 4-fluoro-3-methyl- Molecular Weight 149.16 pKa (Predicted) Value: 16.70±0.30 | Condition: Most;1H-INDOLE, 4-FLUORO-3-METHYL-
• CAS NO: 1011484-22-2
• Molecular Formula: C₉H₈FN
• Molecular Weight: 149.1649232
• Mol File: 1011484-22-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-FLUORO-3-METHYL-1H-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-3-METHYL-1H-INDOLE(1011484-22-2)
• EPA Substance Registry System: 4-FLUORO-3-METHYL-1H-INDOLE(1011484-22-2)

Safety Data

• Hazardous Substances Data: 1011484-22-2(Hazardous Substances Data)

Usage

General Description

4-fluoro-3-methyl-1H-indole is a chemical compound with the molecular formula C9H8FN. It is a substituted indole derivative, meaning it has a fluorine atom and a methyl group attached to the basic indole structure. 4-fluoro-3-methyl-1H-indole is commonly used in chemical research and drug development, particularly in the synthesis of pharmaceuticals and fine chemicals. It is known for its potential biological activity, with studies suggesting that it may have antimicrobial and anticancer properties. However, it is important to handle this compound with caution as it is potentially hazardous and harmful if not used properly.

Upstream product

• 387-43-9 4-fluoroindole 
• 23073-31-6 (4-fluoroindol-3-yl)carboxaldehyde 
• 1443754-92-4 2-methyl-5-fluoroindolizine 
• 107-11-9 1-amino-2-propene 
• 851368-08-6 1-bromo-2-fluoro-6-iodobenzene 

Relevant articles and documents

Cu-Catalyzed Dimerization of Indole Derived Oxime Acetate for Synthesis of Biimidazo[1,2- a]indoles

A copper-mediated cyclization and dimerization of indole derived oxime acetate was developed to generate a series of biimidazo[1,2-a]indole scaffolds with two contiguous stereogenic quaternary carbons in one step.

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.

Palladium-catalyzed aryl amination-heck cyclization cascade: A one-flask approach to 3-substituted indoles

(Chemical Equation Presented) Two for the price of one: A Pd/dppf-based catalyst provides access to the title compounds from 1,2-dihalogenated aromatic compounds and allylic amines in a single reaction flask. The initial aryl amination step occurs with excellent selectivity for the aryl iodide to ensure the formation of a single indole regioisomer, which can be functionalized in situ by N-arylation (see scheme). dba = dibenzylideneacetone, dppf = 1,1′-bis(diphenylphospanyl)ferrocene.